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Background: Metformin is widely used in the treatment of diabetes, and there is interest in ‘repurposing’ the drug
for cancer prevention or treatment. However, the mechanism underlying the metabolic effects of metformin
remains poorly understood.
Methods: We performed respirometry and stable isotope tracer analyses on cells and isolated mitochondria to
investigate the impact of metformin on mitochondrial functions.
Results: We show that metformin decreases mitochondrial respiration, causing an increase in the fraction of
mitochondrial respiration devoted to uncoupling reactions. Thus, cells treated with metformin become energetically
inefficient, and display increased aerobic glycolysis and reduced glucose metabolism through the citric acid cycle.
Conflicting prior studies proposed mitochondrial complex I or various cytosolic targets for metformin action, but we
show that the compound limits respiration and citric acid cycle activity in isolated mitochondria, indicating that at
least for these effects, the mitochondrion is the primary target. Finally, we demonstrate that cancer cells exposed to
metformin display a greater compensatory increase in aerobic glycolysis than nontransformed cells, highlighting their
metabolic vulnerability. Prevention of this compensatory metabolic event in cancer cells significantly impairs survival.
Conclusions: Together, these results demonstrate that metformin directly acts on mitochondria to limit respiration and
that the sensitivity of cells to metformin is dependent on their ability to cope with energetic stress.
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The biguanide metformin is well established as an im-
portant drug in the treatment of type II diabetes [1-3].
Pharmaco-epidemiologic evidence [4,5] and laboratory
models [6,7] have suggested that metformin may have
antineoplastic actions, and this has led to renewed interest
in the molecular actions of the drug [8]. One popular view
is that metformin acts as an inhibitor of complex I of the
electron transport chain. However, the notion that met-
formin acts directly on mitochondria to inhibit complex I
is controversial [9-15]. Recent work on the sensitivity of
cancer cells to the direct actions of metformin further
highlighted the controversy surrounding the mode of ac-
tion of metformin. These studies demonstrate that cancer* Correspondence: julie.st-pierre@mcgill.ca
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article, unless otherwise stated.cells that are deficient in mitochondrial functions (rho0
cells) are sensitive to the action of metformin [11], and
that cancer cells harboring complex I mutations are more
sensitive to the action of metformin compared with cancer
cells without these mutations [16].
While there is controversy regarding the molecular
mechanisms underlying the action of metformin, there is
a general agreement that the drug causes energetic stress,
and that this results in a variety of cell lineage-specific
secondary effects. The liver is an important target organ in
the context of diabetes. This organ is exposed to a relatively
high concentration of metformin via the portal circulation
following oral ingestion, and hepatocytes express high
levels of membrane transporters required for drug influx
[17]. Metformin-induced hepatocyte energetic stress
leads to a reduction in gluconeogenesis [18-20], leading
to improvements in hyperglycemia and hyperinsulinemia.
These metabolic actions also represent a candidate mech-
anism relevant to the subset of cancers that are insulin-
responsive [21]. Recent work has indicated that metforminentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mitochondrial glycerophosphate dehydrogenase [22].
Understanding the actions of metformin on energy
metabolism, particularly on mitochondrial functions, is
important in the context of interest in ‘repurposing’ the
compound for possible applications in oncology. There
is increasing evidence that mitochondrial metabolism
plays an important role in supporting tumor growth,
by providing ATP as well as metabolic intermediates
that can be used for anabolic reactions [23]. Also,
functional mitochondrial complex I has been shown
to be essential for the promotion of aerobic glycolysis
and the Warburg effect [24]. In support of these
points, PGC-1α or ERRα, two known central regula-
tors of mitochondrial metabolism have been shown to
promote the growth of liver, colon, breast, prostate
and melanoma cancers [25-29]. Here, we demonstrate
the influence of metformin on mitochondrial bioener-
getics in cells and in isolated mitochondria.Methods
Animals, cells and reagents
Wild-type male C57BL/6J mice were purchased from
The Jackson laboratory (Bar Harbour, ME, USA). NT2196
and NMuMG cells were kindly provided by Dr. William
Muller (McGill University, Montréal, Canada) and have
been described elsewhere [30]. MCF7 and MCF10A
cells were purchased from ATCC. All reagents were
purchased from Sigma-Aldrich unless otherwise stated.Cell culture
All cell culture material was purchased from Wisent Inc.
unless otherwise specified. NT2196 and NMuMG cells
were grown as previously published [30]. MCF7 cells
were grown in Dulbecco’s Modified Eagle Medium
(DMEM) media with 10% fetal bovine serum, supple-
mented with penicillin and streptomycin. MCF10A cells
were grown in DMEM/Ham’s F12 50/50 Mix Media
supplemented with 5% horse serum, 20 ng/mL human
epidermal growth factor (hEGF), 0.5 μg/mL hydrocorti-
sone, 10 μg/mL insulin, penicillin and streptomycin. All
cells were grown at 37°C, 5% CO2 (Thermo Forma, Series
II Water Jacketed CO2 Incubator). For the experiments
comparing the impact of growth in glucose or galactose
media on respiration, MCF7 cells were cultured either in
standard glucose DMEM or in galactose (25 mM)
medium that has the same composition as DMEM except
that the glucose has been replaced with galactose. Cells
were cultured in glucose or galactose medium for a period
of 20 to 25 days after being put into culture. Cells were
then treated with either ddH20 (control) or metformin
(0.5 mM) for a period of 24 hours, after which respiration
was assessed as previously described [31].Cell proliferation
A fixed number of cells were plated in 6-well plates (9.6
cm2/well). Every 24 hours, the media was removed and
cells were treated with ddH20 (control) or metformin
(0.5 mM and 5.0 mM). At the respective time points (24,
48, and 72 hours), the media was removed and stored
into tubes (to collect floating cells); the adherent cells
were washed with phosphate buffered saline (PBS), tryp-
sinized and resuspended in the media collected, which
was centrifuged at 2,500 rpm for 5 minutes. The media
was removed (and used for lactate and glucose measure-
ments; The media was removed (and used for lactate
and glucose fold change measurements in the presence
of metformin) and the cell pellet was resuspended), and
the cell pellet was resuspended in a known volume of
fresh media. Both total and live cell counts were obtained
using Trypan Blue Stain (0.4%, Gibco) and a TC10 auto-
mated cell counter (Bio-Rad).Lactate and glucose concentration
MCF10A, MCF7, NT2196 and NMuMG cells were
grown in 6-well plates (9.6 cm2/well) to 60% confluency.
The media in each well was removed and centrifuged at
13,000 rpm for 10 minutes to remove cellular debris,
placed into new tubes and analyzed with a Nova BioProfile
400 analyzer. Wells that contained only media in the ab-
sence of cells were also analyzed in this manner to serve
as blanks. To account for cell number, cells were counted
as described above. To calculate lactate production and
glucose consumption, the concentration of either lactate or
glucose present in each condition was subtracted from that
of blank wells and this value was then normalized for total
cell count.Respiration
Respiration measurements with cultured cells or isolated
mitochondria were performed using a Digital Model
10 Clark Electrode (Rank Brothers, Cambridge, UK).
Respiration with cultured cells was carried out in their
respective growth medium while respiration with isolated
mitochondria was carried out in KHEB (120 mM KCl,
5 mM KH2PO4, 3 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES), 1 mM ethylene glycol
tetraacetic acid (EGTA) and 0.3% bovine serum albumin
(BSA) (w/v), pH 7.2) assay medium. Respiration traces for
isolated mitochondria were digitized using DigitizeIt
Software (Version 1.5). This software extracts values from
traces using the background graph paper found on the
trace as a reference. Simply, the respiration traces were
imported, the axes were defined manually based on the
corresponding values found on the graph paper of the
trace, and data values were generated by the software and
plotted using GraphPad Prism 5 Software.
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Mice were sacrificed at approximately 6 months of age
with approval from the McGill University Animal Care
Committee. Mitochondria from skeletal muscle were
isolated as previously described [32]. The integrity of
mitochondrial suspensions were evaluated by quantifying
respiratory control ratio (RCR) values that are obtained
by dividing the rate of oxygen consumption in the presence
of ADP (state 3) by that in the presence of oligomycin
(state 4). Only mitochondrial suspensions displaying
RCR values greater than 3 in control conditions were used.
Treatment of cells with metformin and respiration
NT2196, NMuMG, MFC10A and MCF7 cells were grown
in the presence of ddH20 (control) or specific doses of
metformin for 24 hours. 1 × 106 cells were used for
respiration measurements. Calculations of coupled and
uncoupled respiration were performed according to [31].
Briefly, coupled respiration is calculated by subtracting
total respiration from oligomycin-insensitive (2.5 μg/mL/
1 × 106 cells) respiration. Uncoupled respiration represents
oligomycin-insensitive respiration. Nonmitochondrial respir-
ation represents respiration that is insensitive to myxothiazol
(10 μM). Cells displayed no detectable nonmitochondrial
respiration.
Treatment of isolated mitochondrial suspensions with
metformin and respiration
For the metformin incubation experiments, mitochondria
(0.6 mg/mL) were incubated in KHEB media at 37°C in
a temperature-controlled water bath (Fisher Scientific,
Isotemp 3006S) in the presence of either complex I
(equimolar 30 mM malate and pyruvate) or complex II
(25 mM succinate and 50 μM rotenone) substrates, either
in the presence of ddH20 (control) or 10 mM metformin for
30 minutes. Samples were resuspended every 10 minutes.
After 30 minutes, the 100 μL reaction was diluted in 400 μL
KHEB media (final equimolar concentration of 6 mM mal-
ate and pyruvate or 5 mM succinate and 10 μM rotenone,
in the absence or presence of 2 mM metformin). Respir-
ation was recorded immediately, followed by the addition of
ADP (500 μM, state 3), oligomycin (2.5 μg oligomycin/mg
mitochondrial protein, state 4) and FCCP (1.5 μM).
Stable isotope tracer analyses in cells and isolated
mitochondria
MCF10A and MCF7 cells were cultured in 6-well plates
(9.6 cm2/well) to 80% confluency, after which ddH20
(control) or metformin (0.5 mM, 5.0 mM) was added to
the media for 24 hours. The media was then exchanged
for [U-13C]glucose (Cambridge Isotope Laboratories,
Tewksbury, MA, USA, CLM-1396, 99% atom 13C)-labeled
media for a period of 1 hour. Cells were then rinsed once
with 4°C saline solution (9 g/L NaCl) and quenched with80% methanol (<20°C). Isolated mitochondria from murine
skeletal muscle were resuspended in KHEB media at a con-
centration of 1.5 mg/mL. Samples were incubated in a
temperature-controlled water bath (Fisher Scientific, Iso-
temp 3006S) at 37°C in the presence of 1 mM malate and 1
mM [U-13C]pyruvate for 30 minutes, either in the presence
of ddH20 (control) or 5 mM metformin. Samples were then
quenched in 80% methanol (<20°C). The remaining proced-
ure is identical for cellular and mitochondrial extracts.
Metabolite extraction was carried by sonication at 4°C
(10 minutes, 30 sec on, 30 sec off, high setting, Diage-
node Bioruptor). Extracts were cleared by centrifuga-
tion (14,000 rpm, 4°C) and supernatants were dried in a
cold trap (Labconco) overnight at -4°C. Pellets were solu-
bilized in pyridine containing methoxyamine-HCl (10 mg/
mL) by sonication and vortex, centrifuged and pellets
were discarded. Samples were incubated for 30 minutes
at 70°C (methoximation), and then were derivetized
with MTBSTFA at 70°C for 1 h. Next, 1 μL was injected
into an Agilent 5975C GC/MS configured for single ion
monitoring (SIM) according to [33]. Data analyses were
performed using the Chemstation software (Agilent, Santa
Clara, USA). Mass isotopomer distribution analyses were
performed according to [34,35].
Results
Cancer cells devote a larger fraction of their respiration
to uncoupled reactions than nontransformed cells
In order to assess the dependence of breast cancer cells
on aerobic glycolysis and mitochondrial respiration for
ATP production, we compared these parameters in
murine and human breast cancer cell lines to nontrans-
formed controls. We used NT2196 cells that express
oncogenic Neu/ErbB2 and their parental NMuMG cells
as murine cell line models. For the human cell models,
we used MCF7 cancer cells and MCF10A epithelial cells
as comparative controls. Both NT2196 and MCF7 cancer
cells displayed higher glucose consumption (Figure 1A)
and lactate production (Figure 1B) compared to their
respective controls. These data confirm that aerobic
glycolysis is elevated in cancer cells compared with
nontransformed cells. We next assessed mitochondrial
respiration in breast cancer cells and nontransformed
controls. Mitochondrial respiration can be coupled (linked
to ATP production), or uncoupled (driving proton leak
reactions). NT2196 cancer cells showed reduced mito-
chondrial respiration compared with NMuMG control
cells (Figure 1C). The reduced mitochondrial respiration
was due to a decrease in coupled respiration (Figure 1D).
Uncoupled respiration was similar between murine cancer
cells (NT2196) and their parental controls, while it was
increased in human breast cancer cells (MCF7) com-
pared to control cells (Figure 1E). Coupled respiration
(Figure 1D) was also decreased in MCF7 cells compared
Figure 1 (See legend on next page.)
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Figure 1 Mitochondrial respiration in cancer cells is more uncoupled from ATP production than that in nontransformed cells. Aerobic
glycolysis and mitochondrial respiration were quantified in murine breast cancer cells (NT2196) and parental controls (NMuMG) as well as in human
breast cancer cells (MCF7) and nontransformed controls (MCF10A). (A) Glucose consumption and (B) lactate production in cancer cells are presented
as fold change from controls. (C) Total mitochondrial respiration, (D) coupled respiration and (E) uncoupled respiration in cancer cells are presented as
fold change from controls. (F) The fraction of mitochondrial respiration devoted to coupled and uncoupled respiration was calculated by dividing the
rate of coupled or uncoupled respiration by that of total mitochondrial respiration. Coupled respiration is the respiration used to drive ATP synthesis.
Uncoupled respiration is used to drive proton leak reactions. Data are presented as means ± SEM. n = 3. *P <0.05, Students t-test, where * represents a
significant change from nontransformed controls.
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all mitochondrial respiration compared with controls
(Figure 1C). Next, we quantified the mitochondrial coup-
ling status by calculating the fraction of mitochondrial respir-
ation that was coupled and uncoupled to ATP production.
Breast cancer cells devoted a larger fraction of their mito-
chondrial respiration to drive uncoupling reactions com-
pared with controls (Figure 1F). Conversely, control cells
devoted a larger fraction of their mitochondrial respiration
to support ATP production (Figure 1F). Together, these
data demonstrate that these breast cancer cells have
higher aerobic glycolysis rate than controls, and that
their mitochondria favor uncoupling reactions.
Metformin causes a dose-dependent increase in the
proportion of uncoupled respiration
Metformin caused a dose-dependent decrease in respiration
in MCF7 cancer cells (Figure 2A). This decrease in respir-
ation was due to a reduction in the rate of respiration
used for ATP synthesis (Figure 2B). The rate of uncoupled
respiration was unaffected by the lower doses of metfor-
min, but decreased at 5 mM (Figure 2C). The fact that the
rate of coupled respiration decreased with increasing
doses of metformin, while uncoupled respiration remained
mostly unaffected, caused breast cancer cells to devote
an increasingly higher proportion of their respiration
for uncoupled reactions (Figure 2D). Together, these re-
sults demonstrate that metformin decreases mitochon-
drial respiration, and has a profound impact on the
ability of mitochondria to generate ATP.
Metformin leads to a greater upregulation of aerobic
glycolysis in cancer cells than nontransformed controls
As metformin had a significant impact on mitochondrial
metabolism in breast cancer cells (Figure 2), we then
compared the effect of this drug between cancer cells and
nontransformed controls given that they display differences
in mitochondrial metabolism (Figure 1). Metformin caused
a decrease in mitochondrial respiration in both breast
cancer cells and nontransformed controls (Figures 3A,B).
However, the decrease in respiration was larger in non-
transformed cells compared with breast cancer cells
(Figure 3A,B). Metformin also caused a decrease in res-
piration upon acute treatment (15 minute incubation),[see Additional file 1, Additional file 2: Figure S1] in
the murine control cells (NMuMG), while no change
was observed in the murine breast cancer cells
(NT2196). Furthermore, metformin caused a shift in the
mitochondrial coupling status in favor of uncoupled res-
piration, which was greater in magnitude in nontrans-
formed cells compared with cancer cells (Figure 3C,D).
Both cancer cells and nontransformed controls displayed
elevated aerobic glycolysis upon metformin exposure
(Figures 3E-H). This upregulation of glycolysis will
mitigate the drop in ATP production by mitochondria
caused by metformin. Cancer cells elicited significantly
larger increases in aerobic glycolysis in the presence of
metformin than controls (Figures 3E-H). Despite the
greater compensatory increase in aerobic glycolysis by
cancer cells, their proliferation was equally or even more
affected by metformin treatment than controls (Figures 3I,J).
Indeed, the proliferation of NMuMG and NT2196 was af-
fected similarly by metformin treatment (Figure 3I), while
that of MCF7 was more affected than MCF10A at
earlier time points (Figure 3J). However, all cell lines
showed reduced cell proliferation in the presence of
metformin compared to untreated conditions (Figure 3 I,J).
Overall, failure of the greater compensatory increase in
glycolysis by cancer cells to confer a survival advantage in
the presence of metformin illustrates that these cells
are more energetically stressed by metformin than non-
transformed controls, consistent with the view that trans-
formation is associated with increased ATP demand.
An important implication of these data is that a con-
stant supply of glucose to cells is critical to attenuate the
energetic stress caused by metformin by fuelling aerobic
glycolysis. Therefore, we tested whether cells that are
forced to rely exclusively on mitochondrial metabolism
for ATP production are more sensitive to metformin. We
cultured human breast cancer cells (MCF7) in media where
the glucose had been replaced by galactose [36]. MCF7
cells grown in galactose media displayed an approximate
two-fold increase in mitochondrial respiration compared
with MCF7 cells grown in glucose media (Figure 3K). Im-
portantly, MCF7 cells grown in galactose media de-
voted a larger proportion of their respiration for ATP
production than those grown in glucose (Figure 3L).
These results validate the experimental design by showing
Figure 2 Dose-dependent effects of metformin on mitochondrial respiration. (A) Total, (B) coupled and (C) uncoupled respiration in MCF7
cells after 24 hours of treatment with ddH2O (control) or metformin of varying concentrations (0.05, 0.5 and 5.0 mM). Fold change represents the
change in respiration from untreated samples. (D) The fraction of mitochondrial respiration devoted to coupled and uncoupled respiration was
calculated as in Figure 1. Data are presented as means ± SEM. n = 4 to 5. *P <0.05, One-way ANOVA followed by a Dunnet’s multiple comparison test.
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increase mitochondrial respiration, and elevate the pro-
portion of their mitochondrial respiration devoted to
support ATP production compared to cells grown in
glucose (Figure 3K,L). Metformin caused an approxi-
mate 20% decrease in respiration for MCF7 cells grown
in glucose media (Figure 3K). However, when MCF7
cells were grown in galactose media, metformin had a
more profound impact on mitochondrial respiration,
which decreased by more than two-fold upon metfor-
min treatment (Figure 3K). Metformin caused a sig-
nificant increase in the proportion of uncoupled
respiration for MCF7 cells grown in either glucose or gal-
actose (Figure 3L). However, the impact of metformin on
the proportion of uncoupled respiration was much greater
for MCF7 cells grown in galactose than glucose, given that
at baseline, these cells were more coupled than those grownin glucose (Figure 3L). Importantly, MCF7 cells grown in
galactose media and exposed to 5 mM metformin for 48
hours exhibited strikingly more cell death than MCF7
cells grown in glucose media (Figure 3J,M). Together,
these results demonstrate that cells that cannot engage
aerobic glycolysis due to limiting glucose levels, are
entirely dependent on mitochondria for ATP production,
and are thus more susceptible to the action of metformin.
Metformin diminishes glucose metabolism through the
citric acid cycle
Metformin caused a decrease in mitochondrial respiration
in breast cancer cells as well as in nontransformed con-
trols (Figures 2 and 3). Given the intimate link between
the activity of the electron transport chain and the citric
acid cycle [33,37,38], we investigated the impact of metfor-
min on glucose metabolism through the citric acid cycle
Figure 3 (See legend on next page.)
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Figure 3 Sensitivity of cells to metformin is dependent on the capacity to engage in aerobic glycolysis. (A-B) Total respiration is
presented as fold change upon metformin treatment (0.5mM) from untreated conditions. (C-D) The mitochondrial coupling status represents
coupled and uncoupled respiration as a fraction of total mitochondrial respiration, for both untreated and treated conditions. (E-F) Glucose
consumption, (G-H) lactate production and (I-J) live cell counts of cells treated with metformin (5 mM) for either 24 or 48 hours are represented
as a fold change from untreated conditions. (K) Mitochondrial respiration of MCF7 cells grown in glucose or galactose media in the presence of
ddH20 (control) or metformin (0.5 mM) for 24 hours. Data are normalized to the respiration rate of MCF7 cells in the presence of glucose without
metformin. (L) The fractions of mitochondrial respiration devoted to coupled and uncoupled respiration were calculated as in C-D. (M) Live cell
counts for MCF7 cells cultured in galactose media with treatment of metformin (0.5 or 5.0 mM) for periods of 24, 48 and 72 hours, are represented as
a fold change from untreated conditions. For (A-D), Data are presented as means ± SEM. n = 4, where *P <0.05, Student’s t-test. For (E-J,L,M), data are
presented as means ± SEM. n = 3, # and *P <0.05, Student’s t-test, where * represents a significant change from untreated conditions and # represents
a significant change between indicated cell lines. For (K), data are presented as means ± SEM. n = 3, # and *P <0.05, Student’s t-test, where * represents a
significant change from the respiration rate of MCF7 cells in the presence of glucose without metformin, while # represents a significant change from
the respiration rate of MCF7 cells in the presence of galactose without metformin.
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question, we performed stable isotope tracer analyses
using [U-13C]glucose labeled on all six carbons (m + 6).
Glucose (m + 6) will generate pyruvate (m + 3) through
glycolysis (Figure 4A). Pyruvate (m + 3) can then be con-
verted into lactate (m + 3) through aerobic glycolysis or
into citric acid cycle intermediates (m + 2) through mito-
chondrial metabolism (Figure 4A). Metformin decreased
the labeling of citrate, isocitrate and alpha-ketoglutarate
(m + 2) through the citric acid cycle in MCF7 cancer cells
and controls (Figures 4C-E). These data indicate that less
glucose is entering mitochondrial metabolism in cells
treated with metformin compared with untreated cells.
Furthermore, the proportion taken by citric acid cycle
intermediates within the citric acid cycle changed consid-
erably upon metformin exposure (Figure 4F). Indeed, cells
treated with metformin exhibited a reduced fraction of
citrate and an increased fraction of malate within the citric
acid cycle (Figure 4F). MCF10A cells displayed more
drastic citric acid cycle rearrangement upon metformin
treatment than MCF7 cells, supporting the notion that
cells with high mitochondrial metabolism are more
metabolically responsive to metformin. Contrary to the
decrease in the metabolism of glucose in mitochondria,
metformin caused an increase in the intracellular lactate
to pyruvate ratio in cancer cells and controls, illustrating
that metformin stimulates aerobic glycolysis (Figure 4B).
This result is in agreement with the data presented in
Figure 3 using a different technology. Globally, these
experiments demonstrate that cancer cells treated with
metformin increase the activity of glycolysis, while
decreasing that of the mitochondrial citric acid cycle.
Metformin decreases respiration in isolated mitochondria
Metformin has a profound impact on mitochondrial
metabolism in cells (Figures 2, 3 and 4). In order to assess
whether metformin can directly act on mitochondria,
we tested the impact of metformin on the respiration of
isolated mitochondrial suspensions using mitochondria
isolated from skeletal muscle of mice (Figure 5) or fromMCF10A and MCF7 cells [see Additional file 1, Additional
file 2: Figures S2 and S3]. The quality of mitochondrial
suspensions was evaluated using RCR values that are ob-
tained by dividing the rate of oxygen consumption when
mitochondria are actively synthesizing ATP (state 3), by
that when they are driving proton leak reactions (state 4)
[39]. The quality of mitochondrial suspensions isolated
from murine skeletal muscle was high, with RCR values
above 10 (Figures 5A,B).
To probe the impact of metformin on mitochondria,
we used mitochondria that were incubated with either
complex I or II substrates. Comparison of the effect of
metformin on the respiration rate of mitochondria that
were incubated with complex I or II substrates allows
one to pinpoint whether metformin is acting on complex
I or II, given that complexes III to V are involved in both
complex I- and II-dependent respiration. Metformin re-
duced state 3 and state 4 respiration, as well as the
maximal respiratory capacity of mitochondria respiring
on complex I substrates (Figure 5C,E), but had no sig-
nificant effect on these parameters when mitochondria
were respiring on complex II substrates (Figure 5D,F).
Finally, metformin also acutely decreased complex I-
dependent respiration in isolated mitochondria from
cultured MCF7 and MCF10A cells [see Additional file 1,
Additional file 2: Figures S2 and S3]. Together, these re-
sults demonstrate that metformin can directly act on
mitochondria and limit complex I-dependent respiration.
Metformin reduces citric acid cycle activity in isolated
mitochondria
Given that metformin can directly inhibit complex I-
dependent respiration in isolated mitochondria, we assessed
whether metformin could impact the metabolism of sub-
strates through the citric acid cycle as observed in intact
cells (Figure 4). In order to do this, we performed stable
isotope tracer experiments in isolated mitochondria [34].
Mitochondria were incubated with labeled U−13C
 
pyruvate
(m+ 3) and unlabeled malate (Figure 6A). The U−13C
 
pyru-
vate (m+ 3) generates m+ 2 citric acid cycle intermediates
Figure 4 Metformin reduces glucose metabolism through the citric acid cycle. (A) Schematic depicting glucose carbon flow into glycolysis and
the citric acid cycle (CAC). The usage of tracer metabolites such as [U-13C]glucose where all carbons (12C, white) are replaced by 13C (black circles)
allows for the measurement of CAC activity by gas chromatography/mass spectrometry (GC/MS) analysis and isotopomer enrichments. (B-F) MCF7
and MCF10A cells were treated with ddH2O (control) or metformin (0.5 mM or 5.0 mM) for 24 hours. Cells were then incubated with [U-
13C]glucose
(m+ 6) for 1 hour. (B) Intracellular lactate to pyruvate ratio induced by metformin treatment, displayed as fold change from untreated conditions.
(C) Enrichment of citrate (m+ 2) and (m+ 4), (D), isocitrate (m+ 2) (E) and alpha-ketoglutarate (m + 2) upon incubation with [U-13C]glucose and
quantified as mass isotopomer distributions. (F) CAC intermediates reorganization upon metformin treatment. The sum of the ion intensities for all the
isotopomers of each individual CAC intermediate was normalized to the sum of the ion intensities for all the isotopomers of all combined CAC
intermediates. For B-E, data are presented as mean ± SEM of a representative experiment performed in triplicate of three independent experiments for
control and 0.5 mM metformin treatments, and two independent experiments for 5.0 mM metformin treatment. *P <0.05, Student’s t-test. For F, data
are presented as mean of a representative experiment performed in triplicate of three independent experiments for control and 0.5 mM metformin
treatments, and two independent experiments for 5.0 mM metformin treatment. CAC: citric acid cycle.
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 
pyruvate (m+ 3) can also generate
lactate (m+ 3) given that the enzyme lactate dehydrogenase
is associated with skeletal muscle mitochondria [40].
Metformin decreased the generation of m + 2 citrate,
alpha-ketoglutarate and succinate (Figures 6C-E),illustrating reduced metabolism of pyruvate through
the citric acid cycle. The reduced usage of pyruvate
through the citric acid cycle during metformin treat-
ment was accompanied by an increase in the generation
of lactate (m + 3; Figure 6B), demonstrating that pyruvate
Figure 5 Metformin directly acts on mitochondria to inhibit respiration. (A-B) Design of experiments with isolated mitochondria from murine
skeletal muscle. Mitochondria were incubated with either complex I (malate and pyruvate) or complex II (succinate and rotenone) substrates. Typical
respiratory control ratio (RCR) values are shown for mitochondria respiring on either complex I or II substrates. Respiration in the presence of
substrates is called state 2. Respiration in the presence of ADP where mitochondria are using ADP to make ATP is called state 3. Respiration in the
presence of oligomycin where mitochondria are driving proton leak reactions is called state 4. FCCP stimulates uncoupled respiration and represents
the maximal respiratory capacity. RCR values are calculated by dividing the rate of respiration in state 3 by that in state 4 and are indicative of the
integrity of the mitochondrial suspensions. (C-F) Mitochondria isolated from murine skeletal muscle were incubated with complex I (C,E) or complex II
(D,F) substrates and treated with ddH2O (control) or metformin (2 mM) (E-F). Respiration rates are expressed as the fold difference from untreated
mitochondria. Data are presented as means ± SEM. n = 3. *P <0.05, Student’s t-test.
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http://www.cancerandmetabolism.com/content/2/1/12is diverted away from mitochondrial metabolism. There-
fore, the reduced metabolism of pyruvate through the cit-
ric acid cycle in intact cells upon metformin treatment
(Figure 4) can be captured in isolated mitochondria
(Figure 6).Discussion
Although metformin is widely used in the treatment of
type II diabetes, and is under investigation for possible
utility in cancer treatment, its effects on cellular and
mitochondrial metabolism are incompletely understood.
Figure 6 Metformin inhibits citric acid cycle activity in isolated mitochondria. Mitochondria were incubated with [U-13C]pyruvate (m+ 3) and
unlabeled malate in the presence of ddH2O (control) or metformin (5 mM) for 30 minutes. (A) Schematic depicting stable isotope tracer experiment
where substrates used are uniformly labeled [U-13C]pyruvate and unlabeled malate. The metabolites analyzed in B-E are placed into gray boxes where
the isotopic enrichment is written as m + k where k is the number of 13C (black circles). (B) Enrichment of lactate (m + 3), (C), citrate (m + 2),
(D) alpha-ketoglutarate (m+ 2) and (E) succinate (m+ 2) as evaluated by GC/MS analysis of mass distributions. Data are expressed as normalized ion
amount which represents values obtained from mass isotopomer distribution (MID) × corrected area. Data are presented as means ± SEM. n = 3.
*P <0.05, Student’s t-test (m+ 2 or m+ 3). #P <0.05, Student’s t-test (m + 0).
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http://www.cancerandmetabolism.com/content/2/1/12We show that metformin acts directly on mitochondria
to inhibit complex I-mediated mitochondrial respiration
and citric acid cycle functions. In agreement with our
results obtained with isolated mitochondria, cells treated
with metformin display reduced glucose metabolism
through the citric acid cycle, in addition to showing an
overall decrease in mitochondrial respiration, and a shift
in favor of uncoupling reactions. As a result, mitochon-
drial metabolism becomes energetically inefficient, and
cells compensate for this limitation in ATP production
by increasing aerobic glycolysis (Figure 7).
Our results confirm that mitochondria are key targets
of metformin despite reports suggesting cytoplasmicactions [11,13]. This is in keeping with prior evidence
for an inhibitory effect on complex I together with a
membrane potential-driven accumulation of positively
charged drug within the mitochondrial matrix [14].
Our data argue against an indirect action of metformin
on mitochondria [9]. While this manuscript was in
preparation, a study by the Chandel group has shown
that the ability of metformin to limit tumour growth
in vivo is dependent on mitochondrial complex I [41].
Also, a study by the Hirst group has demonstrated that
metformin can limit the activity of purified complex I
[42]. These papers support our data showing a direct
effect of metformin on mitochondrial respiration.
Figure 7 Metformin directly acts on mitochondria and shifts the balance between coupling and uncoupling reactions. Metformin is
transported into cells through the OCT family of transporters, where it acts on mitochondria to inhibit complex I-dependent respiration and
increase the proportion of uncoupled respiration. Cells respond by increasing glycolysis, ultimately leading to increased lactate production.
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http://www.cancerandmetabolism.com/content/2/1/12There is clinical [43] and experimental [44] evidence
that metformin use is associated with modest weight
loss, in contrast to many antidiabetic medications. This
is consistent with our observation that metformin causes
inefficient mitochondrial metabolism, as demonstrated
by the increase in the fraction of uncoupled respiration.
Classic uncouplers also cause inefficient mitochondrial
metabolism and have been shown to cause substantial
weight loss, but are too toxic for clinical use [45]. Interest-
ingly, recent preclinical work suggests that targeting the un-
coupling agent DNP to the liver, the organ most impacted
by metformin due to its pharmacokinetics following oral
administration, reduces toxicity [46]. However, it is import-
ant to recognize that although metformin causes inefficient
mitochondrial metabolism, it should not be considered as a
classic uncoupler.
Recently, it has been shown that cancer cells that are
more sensitive to low glucose are defective in oxidative
phosphorylation (OXPHOS) regulation and more sensi-
tive to biguanides [16]. The low glucose condition is a
setting that is advantageous for cells displaying robust
mitochondrial capacities, due to the fact that cells need
to rely on alternate fuel sources that are metabolized by
mitochondria [38,47]. Furthermore, because they inhibit
mitochondrial metabolism, biguanides exacerbate the
OXPHOS defects of cells sensitive to low glucose, explain-
ing their greater sensitivity to metformin under low
glucose conditions [16]. We found that cells cultured in
the absence of glucose and in the presence of galactose
displayed increased mitochondrial metabolism and were
drastically more sensitive to the effects of metformin than
cells grown in the presence of glucose. It has also been
shown that cancer cells grown in the absence of glucoseand presence of glutamine were more affected by met-
formin treatment than cells grown in the presence of
glucose [48]. Together, these data support the notion
that metformin inhibits OXPHOS, and thus cells that
are forced to rely on OXPHOS are more affected by the
actions of metformin. Furthermore, these data show
that in the setting of inhibition of OXPHOS, cancer cells
compensate by increasing glycolysis. We demonstrate
that when metformin inhibits OXPHOS, either in iso-
lated mitochondria or in intact cells, the citric acid cycle
is inhibited, and accepts less glucose carbon, thus
favoring lactic acid production. Importantly, if this com-
pensation is restricted by a lack of glucose, or by inhib-
ition of oncogenes that drive glycolysis [29,49], even in
the presence of other nutrients that require mitochon-
drial function for generation of ATP, cell viability is
threatened.
While the concept of inducing energetic stress in can-
cers by using metformin is appealing, pharmacokinetic
issues must be considered. It is by no means clear that
conventional anti-diabetic doses of metformin achieve
active concentrations in neoplastic tissue. Many cancers
express cell surface transport molecules such as OCT1,
which are required for cellular uptake at low ambient
drug concentrations, at far lower levels than in the liver,
where the drug is active. However, once inside cells, the
greater membrane potential of mitochondria from cancer
cells [50,51] should facilitate metformin uptake compared
with mitochondria from nontransformed cells. Thus,
although metformin at high doses has some in vivo
antineoplastic activity [8], it may be considered a ‘lead
compound’ for pharmacokinetic optimization for possible
applications in oncology.
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We demonstrate that metformin directly acts on mito-
chondria to limit citric acid cycle activity and OXPHOS,
as demonstrated in isolated mitochondria as well as in
intact cells. The metformin-mediated decrease in mito-
chondrial function was accompanied by a compensatory
increase in glycolysis. Hence, the sensitivity of cells to
metformin is dependent on their capacity to engage
aerobic glycolysis. Biguanides could thus potentially be
used in oncology to exploit the metabolic vulnerability of
cancer cells.Additional files
Additional file 1: Supplemental experimental procedures. Acute
treatment of cultured cells with metformin and respiration. Isolation of
mitochondria from cultured cells. Incubation of isolated mitochondria
and monitored respiration.
Additional file 2: Figure S1. Is related to Figure 3A and Figure 3B;
Metformin acutely decreases cellular respiration. Cells in suspension were
treated with either ddH2O (control) or metformin (5 mM) for 15 minutes
in a 37°C CO2 chamber. (A) Mitochondrial, (B) coupled, and (C) uncoupled
respiration was tested immediately. N = 3, *P <0.05, Student’s t-test. Oxygen
consumption rate represents the change in oxygen consumption (chart
units) normalized per minute per 1 × 106 cells, where 1 chart unit is 0.2%
oxygen. Figure S2. is related to Figure 4; Metformin decreases respiration in
isolated mitochondria from cultured cells. (A-B) Isolated mitochondria from
MCF10A and MCF7 cells were incubated with either ddH2O(control) or
metformin (10 mM) for 30 minutes in a 37°C water bath in the presence
of complex I substrates (malate and pyruvate). Respiration was tested
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(C-D) Fold change values represent fold change from incubated but
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immediately at t = 0 (A). (B) The changes in respiration at the end of the
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(C) and fold change values (D) were calculated from incubated but untreated
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